D. E. Shaw & Co. Inc. Has $13.10 Million Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

D. E. Shaw & Co. Inc. lessened its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 37.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 518,340 shares of the biopharmaceutical company's stock after selling 306,777 shares during the period. D. E. Shaw & Co. Inc. owned about 0.78% of Celldex Therapeutics worth $13,098,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Barclays PLC boosted its stake in shares of Celldex Therapeutics by 140.7% during the 3rd quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company's stock worth $4,431,000 after acquiring an additional 76,207 shares during the last quarter. Mirador Capital Partners LP increased its position in shares of Celldex Therapeutics by 2.9% in the fourth quarter. Mirador Capital Partners LP now owns 119,492 shares of the biopharmaceutical company's stock valued at $3,020,000 after buying an additional 3,345 shares in the last quarter. SG Americas Securities LLC increased its position in Celldex Therapeutics by 24.4% during the fourth quarter. SG Americas Securities LLC now owns 25,283 shares of the biopharmaceutical company's stock worth $639,000 after purchasing an additional 4,967 shares during the last quarter. KBC Group NV increased its stake in Celldex Therapeutics by 79.1% during the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after purchasing an additional 1,647 shares during the period. Finally, Sovran Advisors LLC acquired a new stake in shares of Celldex Therapeutics in the 4th quarter valued at $2,867,000.

Analysts Set New Price Targets

CLDX has been the subject of a number of analyst reports. The Goldman Sachs Group cut their price target on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Canaccord Genuity Group assumed coverage on Celldex Therapeutics in a research note on Monday, April 28th. They issued a "buy" rating and a $64.00 target price for the company. UBS Group reduced their price objective on shares of Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Cantor Fitzgerald restated an "overweight" rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Finally, Morgan Stanley reduced their price objective on Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a report on Friday, May 9th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $53.90.

Celldex Therapeutics Stock Performance

CLDX stock traded down $0.47 during midday trading on Monday, reaching $19.98. 75,767 shares of the company traded hands, compared to its average volume of 840,227. The firm has a market capitalization of $1.33 billion, a price-to-earnings ratio of -7.78 and a beta of 1.39. Celldex Therapeutics, Inc. has a 52-week low of $14.40 and a 52-week high of $47.00. The business has a 50 day moving average of $18.91 and a 200-day moving average of $22.55.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). The business had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.08 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. Research analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.